Medical journals have recently. Vitamin D Defi ciency in Dialysis Patients and Its Effect on Various Disease Markers. Methods
|
|
- Barnaby Bruce
- 5 years ago
- Views:
Transcription
1 Patients and Its Effect on Various Disease Markers Adel B. Korkor, MD; Christine M. Bretzmann, PharmD; Daniel C. Eastwood, MS Drs. Korkor and Bretzmann are with Purity Dialysis Centers, Delafi eld, Wisconsin; D. Eastwood is with the Division of Biostatistics, Medical College of Wisconsin, Milwaukee, Wisconsin. BACKGROUND: Epidemiologic data has linked vitamin D defi ciency with a variety of negative health outcomes. The purpose of this study was to determine the prevalence of 25-hydroxy-vitamin D defi ciency in our outpatient dialysis patients and to assess the association between vitamin D level and various markers of disease. METHODS: We performed a cross-sectional study evaluating 25-hydroxy-vitamin D levels in 327 chronic dialysis patients. Associations between vitamin D level and various disease markers were measured using Pearson correlation, Spearman correlation, and Kendall s Tau. RESULTS: Mean 25-hydroxy-vitamin D level was ng/ml. Vitamin D defi ciency, defi ned as 25-hydroxyvitamin D <30 ng/ml, was present in 85% of individuals (277/327). Using a Spearman correlation, there was a statistically signifi cant negative association between vitamin D level and triglycerides and transferrin saturation while a positive association existed with albumin. No other signifi cant correlations were noted. CONCLUSIONS: Although vitamin D defi ciency was highly prevalent in our dialysis patients, we were unable to demonstrate a correlation between a 25-hydroxy-vitamin D level and the majority of disease markers evaluated in this study. Further research is necessary to fully elucidate the consequence of vitamin D defi ciency in patients with end-stage renal disease. Medical journals have recently been inundated with research regarding the potentially detrimental effects of 25-hydroxyvitamin D deficiency. Within the last year alone, studies have been published linking low vitamin D levels to an increased risk for all-cause mortality, cardiovascular disease and mortality, myocardial infarction, fatal stroke, hip fracture, chronic pain, anemia, and upper respiratory tract infection. 1 9 Prior to this, vitamin D deficiency has been implicated as a risk factor for a multitude of illnesses ranging anywhere in severity from influenza to life-threatening cancer. 10,11 These findings are important because they suggest that vitamin D is not only important in optimal skeletal health, but may also play a role in the health of other major organ systems. Although the optimal level of 25- hydroxy-vitamin D has yet to be established, the National Kidney Foundation (NKF) Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines indicate that serum levels of <30 ng/ml are insufficient; 25-hydroxy-vitamin D levels tend to decline with worsening kidney function 1 with 80% to 90% of dialysis patients having serum levels below 30 ng/ml Contributing to this increased prevalence may be the lower exposure to sunlight and lower ingestion of vitamin D rich foods commonly seen in dialysis patients. Additionally, the endogenous synthesis of vitamin D 3 from sunlight has been shown to be altered in individuals with compromised renal function as well as those over 60 years of age, which represent a substantial portion of the dialysis population. 16,17 The majority of studies evaluating the deleterious effects of vitamin D deficiency have excluded patients with severe renal insufficiency. Although Wolf et al 13 showed an increased risk for early mortality in vitamin D deficit hemodialysis patients, much is to be learned regarding the role vitamin D deficiency may play in the many disease processes common to this patient population. The purpose of this study was to determine the prevalence of 25-hydroxyvitamin D deficiency in our outpatient dialysis patients and to assess the association between vitamin D level and various markers of disease. Methods We performed a cross-sectional study evaluating vitamin D levels in chronic dialysis patients from 9 outpatient clinics in southeastern Wisconsin. Serum 25-hydroxyvitamin D levels were measured in July of 2008 using the Diasorin Liaison chemiluminescence assay (Diasorin, Stillwater, œ DOI: /dat November 2009 Dialysis & Transplantation 1
2 TABLE I. Descriptive statistics for vitamin D and various markers of disease. Variable n Mean (SD) 25-hydroxy-vitamin D (ng/ml) (12.7) Age (yrs) (13.6) Parathyroid hormone, intact (pg/ml) Minn.). All blood samples were evaluated at a single laboratory. For the purpose of this study, vitamin D deficiency was defined as a serum 25-hydroxy-vitamin D level of <30 ng/ml. To evaluate the association between 25-hydroxy-vitamin D level and various disease markers, patients charts were reviewed for select laboratory values and dose of epoetin alfa (Epogen; Amgen, Thousand Oaks, Calif.) during the same time period that vitamin D was measured. The variables recorded were primarily focused on 3 disease processes: metabolic (218.8) Alkaline phosphatase (U/L) (71.0) Calcium-phosphorus product (%) (12.9) Hemoglobin (g/dl) (1.4) Hematocrit (%) (4.4) Transferrin saturation (%) (18.4) Epogen dose (units/wk) ,822 (15,125) Albumin (g/dl) (0.4) Cholesterol (mg/dl) (35.4) LDL-C (mg/dl) (27.5) HDL-C (mg/dl) (15.9) Triglycerides (mg/dl) (86.0) Homocysteine ( mol/l) (10.3) Median Minimum Maximum * , , , * Values that were considered undetectable (<7 ng/ml) were denoted a value of 6.9. LCL-C, lowdensity lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol. bone disease, which included measurements for intact parathyroid hormone, alkaline phosphatase, and calcium-phosphorus product; anemia, which included measurements for hemoglobin (Hgb), hematocrit, transferrin saturation, and weekly Epogen dose; and dyslipidemia, which included measurements for total cholesterol, lowdensity lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL- C), and triglycerides. Additional variables recorded included age, albumin, and homocysteine. Laboratory variables were typically measured on the first Monday or Tuesday of the month prior to the initiation of dialysis. With the exception of parathyroid hormone (PTH), which was measured between May and July of 2008, and markers of dyslipidemia (cholesterol, LDL-C, HDL-C, triglycerides) and homocysteine, which were measured in August of 2008, all other variables were measured in July of Weekly Epogen dose was determined by calculating the average dose per week during the month of July The association between 25-hydroxyvitamin D level and hospitalizations, infections, and fractures was also evaluated. A retrospective chart review was performed collecting data on the number of hospital admissions, total number of hospital days, hospital-related infections, and fractures requiring hospitalization. Hospital-related infections included infections requiring hospital admission, infections occurring at the time of hospital admission but not necessarily the primary admitting diagnosis, or infections developing during the course of the hospital stay. All data were collected for an approximate 2-year period prior to when 25-hydroxy-vitamin D levels were drawn (i.e., prior to July of 2008). Because data were collected retrospectively, an assumption was made that vitamin D level did not change during that time period. Statistical Analysis Descriptive statistics, presented as means standard deviation (SD), were used to describe 25-hydroxy-vitamin D level and all other covariates evaluated in this study. 25-hydroxy-vitamin D levels that were undetectable (<7.0 ng/ml) were recorded as 6.9 ng/ml in order to perform statistical analyses. Associations between vitamin D level and various markers of disease were measured using Pearson correlation, Spearman correlation, and Kendall s Tau as appropriate for the type of data that were examined. Because of the large number of associations that were examined, a significance level of 0.01 was used for the interpretation of results in an attempt to reduce the false discovery rate. All statistical analyses were performed by the Biostatistics Division of the Medical College of Wisconsin using SAS version 9.1 (SAS Institute, Inc., Cary, NC). 2 Dialysis & Transplantation November 2009
3 TABLE II. Relationship between 25-hydroxy-vitamin D level and various markers of disease. Results Spearman Correlation Data were obtained from a total of 327 chronic dialysis patients. The mean age of patients was years and 56% (183/327) were male. The majority of patients were receiving hemodialysis (n 305) with a small subset of patients on peritoneal dialysis (n 22). Mean 25-hydroxy-vitamin D level was ng/ml. Mean vitamin D levels were higher in men ( ng/ml) than in women ( ng/ml). The majority of individuals (85% [277/327]) were found to be vitamin D deficient (25- hydroxy-vitamin D <30 ng/ml). Mean values and other descriptive statistics for 25-hydroxy-vitamin D and the covariates evaluated in the study are presented in Table I. Using a Spearman correlation, there was a statistically significant negative association between vitamin D level and triglycerides and transferrin saturation while a positive association existed with albumin (Table II). However, only the association with triglycerides remained significant using a Pearson correlation. No other significant correlations were noted. Data relating to hospitalizations and hospital-related infections and fractures were available in a subset of patients (n 175). The mean number of hospital admissions was and the mean total number of hospital days was Hospital-related infections and fractures requiring hospitalization occurred relatively infrequently with means of and , respectively. No significant associations with 25-hydroxy-vitamin D level were found using any of the statistical analyses. Conclusions Pearson Correlation Variable Coefficient p-value Coefficient p-value Age Parathyroid hormone, intact Alkaline phosphatase Calcium-phosphorus product Hemoglobin Hematocrit Transferrin * saturation Epogen dose (weekly) Albumin * Cholesterol LDL-C HDL-C Triglycerides * <.001 * Homocysteine * Statistically signifi cant correlation (p <.01). A total of 85% of patients in our outpatient dialysis clinics were found to be vitamin D deficient, which compares well with previous reports on this topic. However, because 25-hydroxy-vitamin D measurements were all performed in the summer month of July, it is likely that true prevalence may have been underestimated. When evaluating the relationship between 25-hydroxy-vitamin D and various disease markers, we were only able to identify a weak association between vitamin D level and triglycerides, transferrin saturation, and albumin. Martins et al 18 recently examined the association between cardiovascular risk factors and 25-hydroxyvitamin D level using data from the Third National Health and Nutrition Examination Survey (NHANES III). Similar to findings from our analyses, a significant association was found between hypertriglyceridemia and low vitamin D level. The implication of these findings to the increased cardiovascular mortality seen in dialysis patients has yet to be established. In their evaluation of NHANES III data, Martins et al 18 also found a significant relationship between low albumin and low 25-hydroxy-vitamin D level. Conversely, Melamed et al 1 found no correlation in their analysis of the NHANES III data. Studies conducted in dialysis patients have also yielded conflicting results. 13,19 In our analyses of dialysis patients, we were able to detect a weak positive association between albumin and vitamin D level. Kendrick et al 8 recently examined the association between 25-hydroxy-vitamin D level and Hgb in patients with chronic kidney disease and found that risk for anemia was lowered by 29% for every 10 ng/ml increase in 25-hydroxyvitamin D. Monthly vitamin D (ergocalciferol) replacement therapy decreased the weekly Epogen dose requirements in over 60% of hemodialysis patients according to another study, although Hgb was not significantly changed. 15 We evaluated several markers of anemia including Hgb, hematocrit, transferrin saturation, and weekly Epogen dose and only found a weak negative association with transferrin saturation. Vitamin D deficiency can lead to secondary hyperparathyroidism in individuals with normal renal function. In the study by Dobnig et al 2 which excluded patients with chronic kidney disease, mean PTH levels were 36% higher in the group with the lowest 25-hydroxy-vitamin D levels. œ November 2009 Dialysis & Transplantation 3
4 However, the relationship between PTH and 25-hydroxy-vitamin D has been less clear in clinical trials evaluating dialysis patients. Only a poor correlation between the variables was noted in the large study by Wolf et al 13 evaluating more than 800 hemodialysis patients. Additional studies conducted in dialysis patients have shown a lack of correlation. 19,20 Similarly, no correlation was detected in our analyses evaluating PTH and vitamin D level. Vitamin D deficiency has been associated with low bone mineral density and an increased risk for fracture. 21,22 Vitamin D level did not correlate with any bone disease marker evaluated in our study. Incidence of hospital-related fracture also did not correlate with vitamin D level. However, hospital-related fractures occurred infrequently during the study period making it difficult to draw statistical inferences. Additionally, we examined hospitalizations over a 2-year period, which may not have been sufficient time to assess fracture risk. Cauley et al 6 showed an increased risk for hip fracture with low 25-hydroxy-vitamin D levels, but their observations were completed over a median period of 7.1 years. This was an observational study, and inherent to any study of this nature is the inability to identify causal relationships. For this study, a small subset of variables thought to be related to 25-hydroxyvitamin D was evaluated. However, other variables exist such as history of diabetes mellitus, smoking, hypertension, increased body mass index, and ethnicity that were not measured, but have been shown to be independently associated with vitamin D level. 1,18 Because the statistical analyses utilized for this study did not adjust for these unmeasured variables, it is possible they could have accounted for residual confounding and potentially may have influenced our final results. Laboratory variables evaluated in this study were typically drawn at the beginning of the week as compared with midweek, which may be standard in other dialysis centers. Unfortunately, there remains a lack There remains little evidence showing that treatment of vitamin D defi ciency with replacement therapy actually improves health outcomes. of clear guidelines as to the optimal time to collect laboratory samples in patients undergoing dialysis. Hgb levels, for example, are subject to a dilutional effect with higher interdialytic weight gain. Therefore, Hgb levels drawn on a Monday or Tuesday, when interdialytic weight gains tends to be greater, would be expected to be lower than levels drawn midweek. Hemoglobin levels have been shown to be 0.5 to 0.6 g/dl lower when drawn after a long interdialytic interval (3 d) versus a shorter interval (2 d). 23 However, because differences in patient outcomes relating to timing of Hgb blood sampling are lacking, KDOQI guidelines maintain that Hgb levels can be drawn without regard to dialysis day. Other laboratory variables, such as phosphorus, may be falsely elevated after a long interdialytic interval. Yokoyama et al evaluated hemodialysis patients with serum phosphorus levels >7.0 mg/dl and found that levels were significantly higher when drawn after a 3-day dialysis interval versus midweek (8.11 mg/dl versus 7.13 mg/dl, respectively). 24 Although the timing of blood samples should be considered when interpreting mean laboratory values identified in our study, it should have minimal influence on whether or not the variable correlated with vitamin D level. An additional consideration when evaluating our study findings is that lipid profiles were often drawn in a non-fasting state, particularly when patients were receiving dialysis later in the day. Because eating can potentially increase levels of triglycerides and cholesterol, KDOQI recommends an overnight fast prior to drawing lipid profiles if possible. Although it is possible that mean values for triglycerides and cholesterol were falsely elevated due to non-fasted sampling, this should not have had a significant effect on the interrelationship between these parameters and vitamin D level. Despite evidence showing a strong association between vitamin D deficiency and myriad illnesses, the majority of these findings have been based on epidemiologic data alone. There remains little evidence showing that treatment of vitamin D deficiency with replacement therapy (ergocalciferol or cholecalciferol) actually improves health outcomes. Dialysis patients are at a greater risk for vitamin D deficiency and many of the diseases thought to be associated with it. Randomized controlled trials are necessary to fully elucidate the consequence of vitamin D deficiency in this patient population. D&T References 1. Melamed ML, Michos ED, Post W, Astor B. 25- hydroxy-vitamin D levels and the risk of mortality in the general population. Arch Intern Med. 2008;168: Dobnig H, Pilz S, Scharnagl H. Independent association of low serum 25-hydroxy-vitamin D and 1,25-dihydroxy-vitamin D levels with all-cause and cardiovascular mortality. Arch Intern Med. 2008;168: Wang TJ, Pencina MJ, Booth SL, et al. Vitamin D defi ciency and risk of cardiovascular disease. Circulation. 2008;117: Giovannucci E, Liu Y, Hollis BW, Rimm EB. 25- hydroxy-vitamin D and risk of myocardial infarction in men: a prospective study. Arch Intern Med. 2008;168: Pilz S, Dobnig H, Fischer JE, et al. Low vitamin d levels predict stroke in patients referred to coronary angiography. Stroke. 2008;39: Cauley JA, LaCroix AZ, Wu L, et al. Serum 25- hydroxy-vitamin D concentrations and risk for hip fracture. Ann Intern Med. 2008;149: Atherton K, Berry DJ, Parsons T, et al. Vitamin D and chronic widespread pain in a white middle-aged British population: evidence from a cross-sectional population survey. Ann Rheum Dis. 2009;68: Kendrick J, Smits G, Chonchol M. 25-hydroxyvitamin D and infl ammation and its association with hemoglobin levels and chronic kidney disease. National Kidney Foundation (NKF) 2008 Spring Clinical Meetings. Available at: news/meetings/clinical08/cm08_abstracts. cfm. Accessed February 19, Ginde AA, Mansbach JM, Camargo CA. Association between serum 25-hydroxy-vitamin D level and upper respiratory tract infection in the Third National Health and Nutrition Examination Survey. Arch Intern Med. 2009;169: Cannell JJ, Vieth R, Umhau JC. Epidemic infl uenza and vitamin D. Epidemiol Infect. 2006;134: Lappe JM, Travers-Gustafson D, Davies KM, et al. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr. 2007;85: Levin A, Bakris GL, Molitch M, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int. 2007;71: Wolf M, Shah A, Gutierrez O, et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int. 2007;72: Blair D, Byham-Gray L, Lewis E, McCaffrey S. Prevalence of vitamin D [25(OH)D] defi ciency and effects 4 Dialysis & Transplantation November 2009
5 of supplementation with ergocalciferol (vitamin D2) in stage 5 chronic kidney disease patients. J Ren Nutr. 2008;18: Saab G, Young DO, Gincherman Y, et al. Prevalence of vitamin D defi ciency and the safety and effectiveness of monthly ergocalciferol in hemodialysis patients. Nephron Clin Pract. 2007;150: c Holick MF. Vitamin D and the kidney. Kidney Int. 1987;32: Holick MF, Matsuoka LY, Wortsman J. Age, vitamin D, and solar ultraviolet. Lancet. 1989;2: Martins D, Wolf M, Pan D, et al. Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxy-vitamin D in the United States: data from the Third National Health and Nutrition Examination Survey. Arch Intern Med. 2007;167: Taskapan H, Ersoy FF, Passadakis PK, et al. Severe vitamin D defi ciency in chronic renal failure patients on peritoneal dialysis. Clin Nephrol. 2006;66: Del Valle E, Negri AL, Aguirre C. Prevalence of 25(OH) vitamin D insuffi ciency and defi ciency in chronic kidney disease stage 5 patients in hemodialysis. Hemodial Int. 2007;11: Bischoff-Ferrari HA, Dietrich T, Orav EJ, Dawson-Hughes B. Positive association between 25-hydroxy-vitamin D levels and bone mineral density: a population-based study of younger and older adults. Am J Med. 2004:116: Bischoff-Ferrari HA, Willett WC, Wong JB, et al. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA. 2005;293: Bellizzi V, Minutolo R, Terracciano V, et al. Infl u- ence of the cyclic variation of hydration status on hemoglobin levels in hemodialysis patients. Am J Kidney Dis. 2002;40: Yokoyama K, Katoh N, Kasai K, et al. The infl uence of method of calcium correction and the timing of blood collection on application of the K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Japan. Ther Apher Dial. 2006;10: November 2009 Dialysis & Transplantation 5
Vitamin D and Inflammation
Vitamin D and Inflammation Susan Harris, D.Sc. Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University Boston, MA Vitamin D Liver 25(OH)D storage form nmol/l=ng/ml x 2.5 Renal 1,25(OH)
More informationVITAMIN D TESTING CLINICAL GUIDELINES. Policy Number: PDS Effective Date: January 1, Table of Contents
CLINICAL GUIDELINES VITAMIN D TESTING Policy Number: PDS - 010 Effective Date: January 1, 2013 Table of Contents Page Guidelines 1 BACKGROUND 3 CLINICAL EVIDENCE 5 U.S. FOOD AND DRUG ADMINISTRATION (FDA)
More informationVitamin D. Vitamin functioning as hormone. Todd A Fearer, MD FACP
Vitamin D Vitamin functioning as hormone Todd A Fearer, MD FACP Vitamin overview Vitamins are organic compounds that are essential in small amounts for normal metabolism They are different from minerals
More informationFOR CONSUMERS AND PATIENTS
AVAILABILITY OF VITAMIN D FOR CONSUMERS AND PATIENTS Prof. Heike A. Bischoff-Ferrari, MD, DrPH Centre on Aging and Mobility, University of Zurich Dept. of Rheumatology, University Hospital Zurich Overview
More informationInternational Journal of Health Sciences and Research ISSN:
International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Original Research Article Prevalence and Pattern of Mineral Bone Disorder in Chronic Kidney Disease Patients Using Serum
More informationDo We Do Too Many Parathyroidectomies in Dialysis? Sagar Nigwekar MD, MMSc Massachusetts General Hospital
Do We Do Too Many Parathyroidectomies in Dialysis? Sagar Nigwekar MD, MMSc Massachusetts General Hospital E-mail: snigwekar@mgh.harvard.edu March 13, 2017 Disclosures statement: Consultant: Allena, Becker
More informationVitamin D deficiency as a risk factor for Metabolic Syndrome in Hypertensive Subjects
Original Research Article Vitamin D deficiency as a risk factor for Metabolic Syndrome in Hypertensive Subjects Abhishek Singhai*, Priyanka Pandey, Ashwin Porwal, Rajesh Kumar Jha Associate Professor,
More informationRenal Association Clinical Practice Guideline in Mineral and Bone Disorders in CKD
Nephron Clin Pract 2011;118(suppl 1):c145 c152 DOI: 10.1159/000328066 Received: May 24, 2010 Accepted: December 6, 2010 Published online: May 6, 2011 Renal Association Clinical Practice Guideline in Mineral
More informationProtocol GTC : A Randomized, Open Label, Parallel Design Study of Sevelamer Hydrochloride (Renagel ) in Chronic Kidney Disease Patients.
Protocol GTC-68-208: A Randomized, Open Label, Parallel Design Study of Sevelamer Hydrochloride (Renagel ) in Chronic Kidney Disease Patients. These results are supplied for informational purposes only.
More informationNATIONAL QUALITY FORUM Renal EM Submitted Measures
NATIONAL QUALITY FORUM Renal EM Submitted Measures Measure ID/ Title Measure Description Measure Steward Topic Area #1662 Percentage of patients aged 18 years and older with a diagnosis of CKD ACE/ARB
More informationSensipar. Sensipar (cinacalcet) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.46 Subject: Sensipar Page: 1 of 5 Last Review Date: June 22, 2018 Sensipar Description Sensipar (cinacalcet)
More informationUpdate on vitamin D. J Chris Gallagher Professor of Medicine and Endocrinology Creighton University Omaha,Nebraska USA
Update on vitamin D J Chris Gallagher Professor of Medicine and Endocrinology Creighton University Omaha,Nebraska 68131 USA Cali, Colombia 2016 definitions DRIs are the recommended dietary reference intakes
More informationComplete Medical History
Lab Results for Ben Greenfield Last Test Date: Your medical history is not complete. Complete Medical History Complete Medical History What's Next Blood Draw Blood draw scheduled Complete your medical
More informationAssociation between serum 25-hydroxyvitamin D and depressive symptoms in Japanese: analysis by survey season
University of Massachusetts Amherst From the SelectedWorks of Kalpana Poudel-Tandukar Summer August 19, 2009 Association between serum 25-hydroxyvitamin D and depressive symptoms in Japanese: analysis
More informationHYPOVITAMINOSIS D: A NEW RISK MARKER FOR CARDIOVASCULAR DISEASE
HYPOVITAMINOSIS D: A NEW RISK MARKER FOR CARDIOVASCULAR DISEASE JOSEPH P MCCONNELL, KEVIN F FOLEY, GINA M VARGAS INDEX TERMS: vitamin D, cholecalciferol, hypovitaminosis, 25-hydroxyvitamin D. LEARNING
More informationVitamin D, Sunlight Exposure, and Bone Density in Elderly African American Females of Low Socioeconomic Status
Vol. 42, No. 1 47 Clinical Research and Methods Vitamin D, Sunlight Exposure, and Bone Density in Elderly African American Females of Low Socioeconomic Status Sally P. Weaver, PhD, MD; Cindy Passmore,
More informationNIH Public Access Author Manuscript Int J Cardiol. Author manuscript; available in PMC 2012 May 5.
NIH Public Access Author Manuscript Published in final edited form as: Int J Cardiol. 2011 May 5; 148(3): 387 389. doi:10.1016/j.ijcard.2010.12.036. Is vitamin D deficiency a risk factor for ischemic heart
More informationDiabetes Care Publish Ahead of Print, published online October 21, 2009
Diabetes Care Publish Ahead of Print, published online October 21, 2009 Vitamin D, Parathyroid Hormone and Insulin Resistance Associations of Serum Concentrations of 25-Hydroxyvitamin D and Parathyroid
More informationFOCUS ON CARDIOVASCULAR DISEASE
The Consequences of Vitamin D Deficiency: FOCUS ON CARDIOVASCULAR DISEASE Vitamin D deficiency is a global health problem. With all the medical advances of the century, vitamin D deficiency is still epidemic.
More informationVariable Included. Excluded. Included. Excluded
Table S1. Baseline characteristics of patients included in the analysis and those excluded patients because of missing baseline serumj bicarbonate levels, stratified by dialysis modality. Variable HD patients
More informationShon E. Meek, M.D., Ph.D. Assistant Professor of Medicine
Shon E. Meek, M.D., Ph.D. Assistant Professor of Medicine meek.shon@mayo.edu 2016 MFMER 3561772-1 Update on Vitamin D Shon Meek MD, PhD 20 th Annual Endocrine Update January 30-Feb 3, 2017 Disclosure Relevant
More informationThe Diabetes Kidney Disease Connection Missouri Foundation for Health February 26, 2009
The Diabetes Kidney Disease Connection Missouri Foundation for Health February 26, 2009 Teresa Northcutt, RN BSN Primaris Program Manager, Prevention - CKD MO-09-01-CKD This material was prepared by Primaris,
More informationVitamin D and Calcium Therapy: how much is enough
Vitamin D and Calcium Therapy: how much is enough Daniel D Bikle, MD, PhD Professor of Medicine VA Medical Center and University of California San Francisco DISCLOSURE Nothing to disclose 1 RECOMMENDATIONS
More informationThe Endocrine Society Guidelines
Vitamin D and Calcium Therapy: how much is enough DISCLOSURE Daniel D Bikle, MD, PhD Professor of Medicine VA Medical Center and University of California San Francisco Nothing to disclose RECOMMENDATIONS
More information02/27/2018. Objectives. To Replace or Not to Replace: Nutritional Vitamin D in Dialysis.
To Replace or Not to Replace: Nutritional Vitamin D in Dialysis. Michael Shoemaker-Moyle, M.D. Assistant Professor of Clinical Medicine Objectives Review Vitamin D Physiology Review Current Replacement
More informationChronic kidney disease, hypovitaminosis D, and mortality in the United States
http://www.kidney-international.org & 2009 International Society of Nephrology see commentary on page 931 Chronic kidney disease, hypovitaminosis D, and mortality in the United States Rajnish Mehrotra
More informationS150 KEEP Analytical Methods. American Journal of Kidney Diseases, Vol 55, No 3, Suppl 2, 2010:pp S150-S153
S150 KEEP 2009 Analytical Methods American Journal of Kidney Diseases, Vol 55, No 3, Suppl 2, 2010:pp S150-S153 S151 The Kidney Early Evaluation program (KEEP) is a free, communitybased health screening
More informationUpdate on vitamin D and type 2 diabetes
Emerging Science Update on vitamin D and type 2 diabetes Christy S Maxwell and Richard J Wood The prevalence of type 2 diabetes mellitus continues to climb in many parts of the globe in association with
More informationoriginal Se Hwa Kim 1), Tae Ho Kim 1) and Soo-Kyung Kim 2)
Endocrine Journal 2014, 61 (12), 1197-1204 original Effect of high parathyroid hormone level on bone mineral density in a vitamin D-sufficient population: Korea National Health and Nutrition Examination
More informationmean hemoglobin 11 g/dl (110 g/l) compared to patients with lower mean hemoglobin values (Table 20).
S44 Figure 53 depicts the trend in Epoetin dosing from the 1998 study period to the 2003 study period, with an increasing mean weekly Epoetin dose (units/kg/wk) for patients prescribed Epoetin in lower
More information( ) , (Donabedian, 1980) We would not choose any treatment with poor outcomes
..., 2013 Amgen. 1 ? ( ), (Donabedian, 1980) We would not choose any treatment with poor outcomes 1. :, 2. ( ): 3. :.,,, 4. :, [Biomarkers Definitions Working Group, 2001]., (William M. Bennet, Nefrol
More informationLong-Term Care Updates
Long-Term Care Updates January 2016 By Yunuo (Enora) Wu, PharmD Chronic kidney disease (CKD) is defined as kidney damage (including structural or functional abnormalities) or glomerular filtration rate
More informationVITAMIN D AND THE ATHLETE
VITAMIN D AND THE ATHLETE CONSIDERATIONS FOR THE PRACTITIONER Written by Bruce Hamilton, Qatar Vitamin D is a steroid hormone that has previously been given little attention, partially as a result of its
More informationVitamin D & Cardiovascular Disease
Vitamin D & Cardiovascular Disease Disclosures None Vitamin D Objectives: Discuss the basics of vitamin D metabolism Discuss the role of vitamin D deficiency in the development of coronary disease Review
More informationSupplementary Online Content
Supplementary Online Content Bischoff-Ferrari HA, Dawson-Hughes B, Orav EJ, et al. Monthly high-dose vitamin D treatment for the prevention of functional decline: a randomized clinical trial. JAMA Intern
More informationStatus of the CKD and ESRD treatment: Growth, Care, Disparities
Status of the CKD and ESRD treatment: Growth, Care, Disparities United States Renal Data System Coordinating Center An J. Collins, MD FACP Director USRDS Coordinating Center Robert Foley, MB Co-investigator
More informationEpogen / Procrit. Epogen / Procrit (epoetin alfa) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.10.06 Section: Prescription Drugs Effective Date: April1, 2014 Subject: Epogen / Procrit Page: 1 of 7
More informationAnalytical Methods: the Kidney Early Evaluation Program (KEEP) The Kidney Early Evaluation program (KEEP) is a free, community based health
Analytical Methods: the Kidney Early Evaluation Program (KEEP) 2000 2006 Database Design and Study Participants The Kidney Early Evaluation program (KEEP) is a free, community based health screening program
More informationANEMIA & HEMODIALYSIS
ANEMIA & HEMODIALYSIS The anemia of CKD is, in most patients, normocytic and normochromic, and is due primarily to reduced production of erythropoietin by the kidney and to shortened red cell survival.
More informationAssessment of vitamin D levels in patients with acute coronary syndrome
ORIGINAL ARTICLE East J Med 21(4): 178-182, 2016 Assessment of vitamin D levels in patients with acute coronary syndrome Hakki Simsek and Naci Babat * Yuzuncu Yil University, Faculty of Medicine, Cardiology
More informationCAD in Chronic Kidney Disease. Kuang-Te Wang
CAD in Chronic Kidney Disease Kuang-Te Wang InIntroduction What I am going to talk about: CKD and its clinical impact on CAD Diagnosis of CAD in CKD PCI / Revasc Outcomes in CKD CKD PCI CAD Ohtake T,
More informationMultiphasic Blood Analysis
Understanding Your Multiphasic Blood Analysis Test Results Mon General thanks you for participating in the multiphasic blood analysis. This test can be an early warning of health problems, including coronary
More informationTotal Cholesterol A Type of Fat. LDL "Bad" Cholesterol. HDL "Good" Cholesterol. Triglycerides Type of Fat. vldl-c Precursor to LDL Cholest
Lab Results for Ben Greenfield Last Test Date: 2013-08-13 Let us know what you think How likely are you to recommend WellnessFX to a friend or colleague? 1 2 3 4 5 6 7 Not at all likely Neutral Extremely
More informationLiterature Scan: Erythropoiesis Stimulating Agents
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationVitamin D Deficiency. Decreases renal calcium excretion. Increases intestinal absorption Calcium. Increases bone resorption of calcium
Vitamin D Deficiency Deborah Gordish, MD Assistant Professor of Clinical Internal Medicine Lead Physician Lewis Center Primary Care Associate Division Director General Internal Medicine The Ohio State
More informationOriginal Article INTRODUCTION
Original Article The effect of Vitamin D administration on treatment of anemia in end-stage renal disease patients with Vitamin D deficiency on hemodialysis: A placebo-controlled, double-blind clinical
More informationCLINICAL PRACTICE GUIDELINE CKD-MINERAL AND BONE DISORDERS (CKD-MBD) Final Version (01/03/2015)
CLINICAL PRACTICE GUIDELINE CKD-MINERAL AND BONE DISORDERS (CKD-MBD) Final Version (01/03/2015) Dr Simon Steddon, Consultant Nephrologist, Guy s and St Thomas NHS Foundation Trust, London Dr Edward Sharples,
More informationOutline. The Role of Vitamin D in CKD. Essential Role of Vitamin D. Mechanism of Action of Vit D. Mechanism of Action of Vit D 7/16/2010
Outline The Role of Vitamin D in CKD Priscilla How, Pharm.D., BCPS Assistant Professor National University of Singapore Principal Clinical Pharmacist National University Hospital (Pharmacy and Nephrology,
More informationIntravenous Iron Requirement in Adult Hemodialysis Patients
Intravenous Iron Requirement in Adult Hemodialysis Patients Timothy V. Nguyen, PharmD The author is a clinical pharmacy specialist with Holy Name Hospital in Teaneck, New Jersey. He is also an adjunct
More informationBone and Mineral. Comprehensive Menu for the Management of Bone and Mineral Related Diseases
Bone and Mineral Comprehensive Menu for the Management of Bone and Mineral Related Diseases Innovation to Assist in Clinical Diagnosis and Treatment DiaSorin offers a specialty line of Bone and Mineral
More informationPREVALENCE AND PATTERNS OF HYPERPARATHYROIDISM AND MINERAL BONE DISEASE IN PATIENTS WITH CHRONIC KIDNEY DISEASE AT KENYATTA NATIONAL HOSPITAL
PREVALENCE AND PATTERNS OF HYPERPARATHYROIDISM AND MINERAL BONE DISEASE IN PATIENTS WITH CHRONIC KIDNEY DISEASE AT KENYATTA NATIONAL HOSPITAL DR. ANNE MUGERA The Problem Chronic Kidney disease is a worldwide
More informationA pilot Study of 25-Hydroxy Vitamin D in Egyptian Diabetic Patients with Diabetic Retinopathy
A pilot Study of 25-Hydroxy Vitamin D in Egyptian Diabetic Patients with Diabetic Retinopathy El-Orabi HA 1, Halawa MR 1, Abd El-Salam MM 1, Eliewa TF 2 and Sherif NSE 1 Internal Medicine and Endocrinology
More informationCONCORD INTERNAL MEDICINE CHRONIC KIDNEY DISEASE PROTOCOL. Revised May 30, 2012
CONCORD INTERNAL MEDICINE CHRONIC KIDNEY DISEASE PROTOCOL Douglas G. Kelling, Jr., MD C. Gismondi-Eagan, MD, FACP George C. Monroe III, MD Revised May 30, 2012 The information contained in this protocol
More informationVitamin D Status among Patients Attending Hussein Medical Center for Diabetes in Jordan
Vitamin D Status among Patients Attending Hussein Medical Center for Diabetes in Jordan Muwafag Hyari MD*, Hala Abu-Romman MD ** ABSTRACT Objective: Vitamin D is a steroid fat soluble vitamin, in which
More informationVitamin D therapy in patients with primary hyperparathyroidism and hypovitaminosis D
European Journal of Endocrinology (2009) 161 189 193 ISSN 0804-4643 CLINICAL STUDY Vitamin D therapy in patients with primary hyperparathyroidism and hypovitaminosis D J R Tucci 1,2,3 1 Division of Endocrinology,
More informationVitamin D Replacement ROCKY MOUNTAIN MEETING NOV 2013 BANFF W.COKE UNIVERSITY OF TORONTO
Vitamin D Replacement ROCKY MOUNTAIN MEETING NOV 2013 BANFF W.COKE UNIVERSITY OF TORONTO Disclosures: (Academic Mea Culpa) No financial conflicts I have no expertise re: Vitamin D. OBJECTIVES: 1) Review
More informationAETNA BETTER HEALTH Prior Authorization guideline for Erythropoiesis Stimulating Agents (ESA)
AETNA BETTER HEALTH Prior Authorization guideline for Erythropoiesis Stimulating Agents (ESA) Drugs Covered Procrit Epogen Aranesp Authorization guidelines For patients who meet all of the following: Does
More informationAlex Chin. Opinion Letter VITAMIN D ANA. Dr. Alex Chin T2L 2K8. in laboratory
Vitamin D Analyte of thee Millennium OPINION LETTER VITAMIN Alex Chin D ANA Calgary Laboratory Services, Calgary, Alberta Canadaa & Department of Pathology and Laboratory Medicine, University of Calgary,
More informationAranesp. Aranesp (darbepoetin alfa) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.85.01 Subject: Aranesp Page: 1 of 6 Last Review Date: September 15, 2017 Aranesp Description Aranesp
More informationVitamin D: Conflict of Interest Statement Corporate. Outline 7/5/2016
Vitamin D: What s New and Not? Clifford J Rosen MD Maine Medical Center Research Institute rosenc@mmc.org Conflict of Interest Statement Corporate NO STOCKS or EQUITY Editor UpToDate, New England Journal
More informationThe Association of Vitamin D Deficiency and Insufficiency with Diabetic Nephropathy: Implications for Health Disparities
The Association of Vitamin D Deficiency and Insufficiency with Diabetic Nephropathy: Implications for Health Disparities Vanessa A. Diaz, MD, MS, Arch G. Mainous III, PhD, Peter J. Carek, MD, MS, Andrea
More informationKIDNEY DISEASE is associated with a number
PATIENT EDUCATION Column Editor: Beth McQuiston, MS, RD, LD Tips for Cholesterol Control in Patients on Hemodialysis Philippa Norton Feiertag, MEd, RD, CSR, LD Submitted by Philippa Norton Feiertag, MEd,
More information15/9/2017 4:21:00PM 15/9/2017 4:29:07PM 19/9/2017 7:27:01PM A/c Status. Test Name Results Units Bio. Ref. Interval Bilirubin Direct 0.
LL - LL-ROHINI (NATIONAL REFERENCE 135091254 Age 30 Years Gender Male 15/9/2017 42100M 15/9/2017 42907M 19/9/2017 72701M Ref By Final SWASTH SUER 3 LIVER & KIDNEY ANEL, SERUM (Spectrophotometry, Indirect
More informationLesson #7: Quality Assessment and Performance Improvement
ESRD Update: Transitioning to New ESRD Conditions for Coverage Student Manual Lesson #7: Quality Assessment and Performance Improvement Learning Objectives At the conclusion of this lesson, you will be
More informationCardiovascular Mortality: General Population vs ESRD Dialysis Patients
Cardiovascular Mortality: General Population vs ESRD Dialysis Patients Annual CVD Mortality (%) 100 10 1 0.1 0.01 0.001 25-34 35-44 45-54 55-64 66-74 75-84 >85 Age (years) GP Male GP Female GP Black GP
More informationLab Values Explained. working at full strength. Other possible causes of an elevated BUN include dehydration and heart failure.
Patient Education Lab Values Explained Common Tests to Help Diagnose Kidney Disease Lab work, urine samples and other tests may be given as you undergo diagnosis and treatment for renal failure. The test
More informationTestosterone Therapy in Men An update
Testosterone Therapy in Men An update SANDEEP DHINDSA Associate Professor of Medicine Director, Division of Endocrinology and Metabolism, Saint Louis University, St. Louis, MO Presenter Disclosure None
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Solomon SD, Uno H, Lewis EF, et al. Erythropoietic response
More informationVitamin D Therapy in Patients with Primary Hyperparathyroidism and Hypovitaminosis D
Page 1 of 17 Accepted Preprint first posted on 21 April 2009 as Manuscript EJE-08-0901 Vitamin D Therapy in Patients with Primary Hyperparathyroidism and Hypovitaminosis D JR Tucci, MD, FACP, FACE, Director,
More informationPredictors of Vitamin D Deficiency in Predialysis Patients with Stage 3 5 Chronic Kidney Diseases in Southern China
Original Article Predictors of Vitamin D Deficiency in Predialysis Patients with Stage 3 5 Chronic Kidney Diseases in Southern China M Feng, J Lv, FT Huang 1, PF Liang, S Fu, YC Zeng, Y Tang, AP Xu Departments
More informationSung-Woo Han, Sung-Jin Kim, Duck-Joo Lee, Kwang-Min Kim, Nam-Seok Joo*
Korean J Fam Med. 2014;35:98-106 http://dx.doi.org/10.4082/kjfm.2014.35.2.98 The Relationship between Serum 25-Hydroxyvitamin D, Parathyroid Hormone and the Glomerular Filtration Rate in Korean Adults:
More informationPersistent post transplant hyperparathyroidism. Shiva Seyrafian IUMS-97/10/18-8/1/2019
Persistent post transplant hyperparathyroidism Shiva Seyrafian IUMS-97/10/18-8/1/2019 normal weight =18-160 mg In HPT= 500-1000 mg 2 Epidemiology Mild 2 nd hyperparathyroidism (HPT) resolve after renal
More informationDiabetes Day for Primary Care Clinicians Advances in Diabetes Care
Diabetes Day for Primary Care Clinicians Advances in Diabetes Care Elliot Sternthal, MD, FACP, FACE Chair New England AACE Diabetes Day Planning Committee Welcome and Introduction This presentation will:
More informationStudy of Vitamin D Deficiency among the Elderly; Insights from Qatar
Study of Vitamin D Deficiency among the Elderly; Insights from Qatar Dr. NavasNadukkandiyil, M.D Investigators Hanadi Khamis Al hamad, MD, NavasNadukkandiyil, MD, Ayman El- Menyar, MSc, FRCP, FACC, Luay
More informationSCIENTIFIC STUDY REPORT
PAGE 1 18-NOV-2016 SCIENTIFIC STUDY REPORT Study Title: Real-Life Effectiveness and Care Patterns of Diabetes Management The RECAP-DM Study 1 EXECUTIVE SUMMARY Introduction: Despite the well-established
More informationChapter 3.1: Diagnosis of CKD MBD: biochemical abnormalities Kidney International (2009) 76 (Suppl 113), S22 S49. doi: /ki.2009.
chapter 3.1 http://www.kidney-international.org & 2009 KDIGO Chapter 3.1: Diagnosis of CKD MBD: biochemical abnormalities. doi:10.1038/ki.2009.191 Grade for strength of recommendation a Strength Wording
More informationConversion Dosing Guide:
Conversion Dosing Guide: From epoetin alfa to Aranesp in patients with anemia due to CKD on dialysis Indication Aranesp (darbepoetin alfa) is indicated for the treatment of anemia due to chronic kidney
More informationZeenat Ali, PGY3 Joseph Grisanti, MD June 7 th, 2012
A Randomized Open Label Trial to Evaluate the Efficacy of Different Dosage Forms of Vitamin D in Patients with Vitamin D Deficiency, and the Effect of Food on Vitamin D Absorption. Zeenat Ali, PGY3 Joseph
More informationTables of Normal Values (As of February 2005)
Tables of Normal Values (As of February 2005) Note: Values and units of measurement listed in these Tables are derived from several resources. Substantial variation exists in the ranges quoted as normal
More informationDiabetes Mellitus: A Cardiovascular Disease
Diabetes Mellitus: A Cardiovascular Disease Nestoras Mathioudakis, M.D. Assistant Professor of Medicine Division of Endocrinology, Diabetes, & Metabolism September 30, 2013 1 The ABCs of cardiovascular
More informationMonth/Year of Review: September 2012 Date of Last Review: September 2010
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationChronic Kidney Disease as cardiovascular risk predictor Evidence based clinical management. Fabio Mazza
Chronic Kidney Disease as cardiovascular risk predictor Evidence based clinical management Fabio Mazza CKD (Chronic Kidney Disease) is an ever-increasing clinical condition marked by a progressive reduction
More informationChapter Five Clinical indicators & preventive health
Chapter Five Clinical indicators & preventive health The painter who draws merely by practice and by eye, without any reason, is like a mirror which copies every thing placed in front of it without being
More informationChronic Kidney Disease
Chronic Kidney Disease Chronic Kidney Disease (CKD) Guideline (2010) Chronic Kidney Disease CKD: Executive Summary of Recommendations (2010) Executive Summary of Recommendations Below are the major recommendations
More informationMagnetic resonance imaging, image analysis:visual scoring of white matter
Supplemental method ULSAM Magnetic resonance imaging, image analysis:visual scoring of white matter hyperintensities (WMHI) was performed by a neuroradiologist using a PACS system blinded of baseline data.
More informationThe Vitamin D Gap. Vitamin D intake guidelines were established to prevent. Estimating an adequate intake of vitamin D. FEATURE VITAMIN D GAP
The Vitamin D Gap Estimating an adequate intake of vitamin D. By Laurence Montgomery, ND and George Tardik, ND Vitamin D intake guidelines were established to prevent rickets in children and osteomalacia
More informationPART FOUR. Metabolism and Nutrition
PART FOUR Metabolism and Nutrition Advances in Peritoneal Dialysis, Vol. 21, 2005 Maria Mesquita, 1 Eric Wittersheim, 2 Anne Demulder, 2 Max Dratwa, 1 Pierre Bergmann 3 Bone Cytokines and Renal Osteodystrophy
More informationVitamin D receptor gene polymorphism and serum levels of Fetuin-A, Vitamin D and ipth in the hemodialysis patients
In The Name of GOD Vitamin D receptor gene polymorphism and serum levels of Fetuin-A, Vitamin D and ipth in the hemodialysis patients Authors & Affiliations: 1-jamal hallajzadeh; Maraghe University of
More informationHTA ET DIALYSE DR ALAIN GUERIN
HTA ET DIALYSE DR ALAIN GUERIN Cardiovascular Disease Mortality General Population vs ESRD Dialysis Patients 100 Annual CVD Mortality (%) 10 1 0.1 0.01 0.001 25-34 35-44 45-54 55-64 66-74 75-84 >85 Age
More informationCKD FOR INTERNISTS. Dr Ahmed Hossain Associate professor Medicine Sir Salimullah Medical College
CKD FOR INTERNISTS Dr Ahmed Hossain Associate professor Medicine Sir Salimullah Medical College INTRODUCTION In 2002, the National Kidney Foundation s Kidney Disease Outcomes Quality Initiative(KDOQI)
More informationOSTEOMALACIA UPDATE. Nothing to Disclose. Daniel D Bikle, MD, PhD Professor of Medicine University of California and VA Medical Center San Francisco
OSTEOMALACIA UPDATE Daniel D Bikle, MD, PhD Professor of Medicine University of California and VA Medical Center San Francisco Nothing to Disclose 1 Case History 59 YO WM referred for evaluation of diffuse
More informationKey words: Vitamin D analogues, alfacalcidol, calcitriol, secondary hyperparathyroidism, renal dialysis
Oral cal ORAL CALCITRIOL VERSUS ORAL ALFACALCIDOL FOR THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS RECEIVING HEMODIALYSIS: A RANDOMIZED, CROSSOVER TR IAL Samantha Moe 1, Lori D Wazny 2, Janet
More informationEffects of Diabetes Mellitus, Age, and Duration of Dialysis on Parathormone in Chronic Hemodialysis Patients. Hamid Nasri 1, Soleiman Kheiri 2
Saudi J Kidney Dis Transplant 2008;19(4):608-613 2008 Saudi Center for Organ Transplantation Saudi Journal of Kidney Diseases and Transplantation Original Article Effects of Diabetes Mellitus, Age, and
More informationESPEN Congress Prague 2007
ESPEN Congress Prague 2007 Key papers in the field of nutrition Dietitian Geila S Rozen Key Papers in the field of Nutrition ESPEN 2007 Prague Geila S Rozen Clinical Nutrition Dep. Rambam health campus
More informationTHE NEW ZEALAND MEDICAL JOURNAL
THE NEW ZEALAND MEDICAL JOURNAL Vol 116 No 1179 ISSN 1175 8716 Efficacy of an oral, 10-day course of high-dose calciferol in correcting vitamin D deficiency Fiona Wu, Toni Staykova, Anne Horne, Judy Clearwater,
More informationADVANCES. Annual reports from the Centers for. In Anemia Management. Anemia Management in the United States: Is There Opportunity for Improvement?
ADVANCES Vol. 1 No.1 22 We are pleased to introduce our newest NPA publication, Advances in Anemia Management. This quarterly publication will address contemporary issues relating to the treatment of anemia
More informationCKD and CVD. Jamal Salameh, MD, FACP, FASN First Coast Nephrology
CKD and CVD Jamal Salameh, MD, FACP, FASN First Coast Nephrology An Epidemic of Kidney Disease Prevalence CKD stages 1-4 10% 1988-94 13% 1999-2004 Coresh, JAMA 298:2038, 2007 Stage 5: GFR
More informationFND 431 Clinical Experience Case Study! Introduction!
FND 431 Clinical Experience Case Study Jennifer Millard Introduction Ms. B is a Type II diabetic with ESRD who has been receiving dialysis since April of 2013. Previously, she has shown excellent compliance
More informationNephrology Unit- CHU Liège- Ulg- Belgium
Are the complications of arteriovenous fistulas associated with an abnormal Ankle-Brachial Index in Hemodialysis? A 4y study P. Xhignesse, A. Saint-Remy, B. Dubois, JC. Philips, JM. Krzesinski Nephrology
More informationJOURNAL OF INTERNATIONAL ACADEMIC RESEARCH FOR MULTIDISCIPLINARY Impact Factor 1.393, ISSN: , Volume 2, Issue 7, August 2014
HYPOVITAMINOSIS D IN INDIAN FEMALES WITH POSTMENOPAUSAL OSTEOPOROSIS DR. SHAH WALIULLAH 1 DR. VINEET SHARMA 2 DR. R N SRIVASTAVA 3 DR. YASHODHARA PRADEEP 4 DR. A A MAHDI 5 DR. SANTOSH KUMAR 6 1 Research
More information